Directory
>
Greg Oehrtman
Greg Oehrtman
Scientist, Formulation Development Oral Solids | AVEO Oncology
Massachusetts, Boston, United States
Greg Oehrtman
Summary
Greg Oehrtman is an accomplished leader in the pharmaceutical and biotechnology sectors, currently serving as the VP of Technical Operations at Aveo Oncology. With extensive experience in formulation development and clinical/commercial supply logistics, he has successfully overseen the development of injectable and oral dosage forms for various oncology products. His career spans multiple prestigious organizations where he has led cross-functional teams in the development of innovative drug delivery systems, including reusable injection pens and controlled-release formulations. Greg holds a Ph.D. in Chemical Engineering from MIT, where he focused on bioengineered systems and receptor-ligand interactions. He has a proven track record in regulatory submissions and has authored numerous CMC sections for IND and NDA filings. Beyond his technical expertise, Greg is known for his strategic vision and ability to manage complex projects effectively, driving commercialization efforts from concept to market launch.
Greg Oehrtman
Work Experience
VP of Technical Operations at
AVEO Oncology
August 2022 - Present
Greg Oehrtman
Education
Massachusetts Institute of Technology, Ph.D., Chemical Engineering
The University of Texas at Austin, BS, Chemical Engineering
University of Illinois Urbana-Champaign, MS, Chemical Engineering
Frequently Asked Questions about Greg Oehrtman
What is Greg Oehrtman email address?
Greg Oehrtman's primary email address is *************@quintiles.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Greg Oehrtman work for?
Greg Oehrtman is a Scientist, Formulation Development Oral Solids at AVEO Oncology.
Where Greg Oehrtman graduated from?
Greg Oehrtman holds a degree in Ph.D. Thesis: Quantification of Receptor – Ligand Interactions on Bioengineered Autocrine Cell System – A Comparison on Theory and Experiments Refined an autocrine / antibody inhibitor mathematical model. Developed phosphotyrosine and EGFR ELISAs, and TGFa assays (RIA, RT-PCR / RPA). Developed novel method for quantifying autocrine complexes using Molecular Devices Cytosensor. Advisors: Douglas A. Lauffenburger, MIT, Dept. of Chemical Engineering and H. Steven Wiley, Univ. of Utah – Dept. of Cell Biology Show less from Massachusetts Institute of Technology.
How can I directly contact Greg Oehrtman?
To contact Greg Oehrtman directly, you can use the email address *************@quintiles.com. Complete contact information is available upon registration with Muraena.
Who is Greg Oehrtman?
Greg Oehrtman is an accomplished leader in the pharmaceutical and biotechnology sectors, currently serving as the VP of Technical Operations at Aveo Oncology. With extensive experience in formulation development and clinical/commercial supply logistics, he has successfully overseen the development of injectable and oral dosage forms for various oncology products. His career spans multiple prestigious organizations where he has led cross-functional teams in the development of innovative drug delivery systems, including reusable injection pens and controlled-release formulations. Greg holds a Ph.D. in Chemical Engineering from MIT, where he focused on bioengineered systems and receptor-ligand interactions. He has a proven track record in regulatory submissions and has authored numerous CMC sections for IND and NDA filings. Beyond his technical expertise, Greg is known for his strategic vision and ability to manage complex projects effectively, driving commercialization efforts from concept to market launch.
Greg`s contact details
*************@quintiles.com
*************@stealthpeptides.com
*************@stealthbt.com
*********@aveooncology.com
Colleagues
Conversion Manager
Corps Member/Elementary Special Education Teacher
Sales Analyst
Director of National Accounts
Regional Business Director
Director, Chemical Development
VP of Clinical Development